Skip to main content
HLNCF logo

Haleon plc (HLNCF) Stock Price & Analysis

Haleon plc (HLNCF) — price $4.52 (-0.88%), as of the Nov 19, 2026 trading session; market cap $39.6B.

Educational signal · not a buy or sell recommendation · How to read this

$4.52 −$0.04 (-0.88%) Market Cap $39.6B

Haleon plc · HLNCF · Healthcare · Drug Manufacturers - Specialty & Generic

Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • ZTS · Zoetis Inc. · 87 /100
  • TEVA · Teva Pharmaceutical Industries Limited · 57 /100
  • VTRS · Viatris Inc. · 35 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$4.52
Change on the day-0.88%
52-week range$4.15–$5.75
Market capitalisation$39.6B—
Price / earnings (trailing)18.87
Shares traded on the day1.0K
Beta (volatility vs the S&P 500)0.24

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $4.15, high $5.75, latest $4.52. $5.75 $4.15 high $5.75 Oct 17, 2025 Nov 19, 2026 · $4.52 $4.71Oct 17, 2025$4.63Oct 31, 2025$4.83Nov 14, 2025$4.88Nov 28, 2025$4.79Dec 12, 2025$5.05Dec 26, 2025$4.95Jan 9, 2026$5.10Jan 23, 2026$5.45Feb 6, 2026$5.53Feb 20, 2026$5.11Mar 6, 2026$5.30Mar 20, 2026$4.93Apr 2, 2026$4.82Apr 17, 2026$4.50May 1, 2026$4.45May 15, 2026$4.56May 29, 2026$4.53Jun 12, 2026$4.58Jun 26, 2026$4.83Jul 10, 2026$4.86Jul 24, 2026$4.95Aug 7, 2026$4.81Aug 21, 2026$4.74Sep 4, 2026$4.51Sep 18, 2026$4.46Oct 2, 2026$4.95Oct 16, 2026$4.15Oct 30, 2026$4.55Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Haleon (HLNCF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Negative
Debt/Equity Neutral
ROE Neutral
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Haleon (HLNCF), and what does it report?

Short answer

Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: Building 5, First Floor, THE Heights, Weybridge, X0, KT13 0NY. It employs 24,561 people and is led by Brian James McNamara. In Q2 FY2025 it reported revenue of £2.74B and net income of £403M. The market values it at $39.6B.

2 · Latest results

What do the latest results show for Haleon (HLNCF)?

Short answer · as of

The most recent reported quarter, Q2 FY2025, carried revenue of £2.74B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2025£2.74B£403M£0.04 (diluted)
Q1 FY2025£2.74B£403M£0.04 (diluted)
Q4 FY2024£2.76B£231M£0.03 (diluted)
Q3 FY2024£2.78B£485M£0.05 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Haleon (HLNCF)?

Short answer · as of

The distress and quality screens read Altman Z 2.88 · Piotroski F 7. Trailing ratios: ROE 10.1% · ROA 5.1% · current ratio 0.69.

4 · What to check next?

What should you watch next at Haleon (HLNCF)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $11.32B · EPS 0.21 · 16 analysts.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • The newest quarter held here (Q2 FY2025) was filed Jun 30, 2025 — 8 months ago.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$11.32B
EPS estimate
$0.21

Measured against a quoted price of $4.52 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held HLNCF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported HLNCF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Haleon (HLNCF)?

Read these with our analysis →

What Investors Ask About Haleon (HLNCF) — Healthcare

Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.

Why does Haleon appear under drug manufacturers when it owns Sensodyne and Centrum?

The classification groups Haleon with specialty and generic drug producers, but its operating description is that of a global consumer healthcare company. Sensodyne, Centrum, Panadol, and its related brands generate sales through consumer health categories supported by production, distribution, and marketing.

How do Panadol, Voltaren, and Advil fit Haleon’s model?

They anchor Haleon’s pain-management offering within a broader portfolio that also covers oral health, respiratory care, digestive health, and supplements. Their role is to turn Haleon’s research, manufacturing, distribution, and promotional capabilities into repeat consumer demand across markets.

What is the HLNCF stock price today?

The last price recorded for Haleon plc (HLNCF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 23 figures on this page — 1 from SEC filings and earnings calls, 15 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • FAQ: Why does Haleon appear under drug manufacturers when it owns Sensodyne and Centrum?: Sector / industry (provider taxonomy); Business description
  • FAQ: How do Panadol, Voltaren, and Advil fit Haleon’s model?: Business description; Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.